Bye bye gadolinium! PRIME demonstrates bpMRI as good as mpMRI
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Bye bye gadolinium! PRIME demonstrates bpMRI as good as mpMRI
-
Narrado por:
-
De:
Big news today with the publication in JAMA of the eagerly anticipated PRIME study, a prospective multicentre trial comparing biparametric (bp) with multiparametric (mp) MRI in men suspected of having prostate cancer. Of course, mpMRI includes contrast enhanced sequences following injection of gadolinium, adding time, cost, plus the burden of gadolinium to bpMRI, and there have been suggestions that bpMRI may be just as effective as mpMRI for detecting clinically significant prostate cancer.
We are joined today by trial PI Veeru Kasivisvanathan (Urologist, UCL, London), and Francesco Giganti (Radiologist, UCL, London), to discuss the findings and what this means going forward. And it is all good news!
Your host Declan Murphy is on his own today while Renu Eapen on the road in Singapore.
Even better on our YouTube channel
Links below:
JAMA paper published today
Twitter: @compassurology @veerukasi @giga_fra
Website: compassurology.org
Funders:
John Black Charitable Foundation, Prostate Cancer UK, European Association of Urology Research Foundation, Wolfgang.Dieckmann Foundation.